IOVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Acti Jul 10, 2025 04:44PM
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Jul 6, 2025 10:30AM
IOVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - IOV Jul 4, 2025 12:17PM
IOVA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Act Jul 1, 2025 11:02AM
IOVA FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Jun 28, 2025 11:52AM


Jun 27, 2025 11:30AM IOVA DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securit
Jun 22, 2025 09:15AM ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 21, 2025 08:30AM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 18, 2025 01:04PM ROSEN, A TOP RANKED LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 11, 2025 11:10PM ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 8, 2025 12:35PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 5, 2025 04:06PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Jun 3, 2025 03:37PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
May 30, 2025 07:16PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
May 25, 2025 01:17PM ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
May 23, 2025 12:15PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
May 19, 2025 06:38PM ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Sep 12, 2022 07:00AM Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
Sep 12, 2022 07:00AM Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
May 28, 2020 09:03AM Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)
May 29, 2019 08:00AM Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
May 29, 2019 08:00AM Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
Jun 6, 2018 08:00AM Advaxis Appoints Molly Henderson as Chief Financial Officer
Dec 13, 2017 06:30AM BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics